Table 1.
Characteristics of the SIRCA Study Sample
| Men (n=457) | Women (n=403) | |
|---|---|---|
| Median (Q1 – Q3) | Median (Q1 – Q3) | |
| Age (years) | 46 (40 – 51) | 50 (44 – 57) |
| Total Cholesterol (mg/dL) | 199 (174 – 224) | 211 (183 – 234) |
| LDL-Cholesterol (mg/dL) | 126 (102 – 148) | 125 (101 – 147) |
| HDL-Cholesterol (mg/dL) | 42 (36 – 49) | 58 (47 – 68) |
| Triglycerides (mg/dL) | 126 (91 – 177) | 112 (80 – 147) |
| 10 year CAD Framingham Risk (%) | 7 (4 – 8) | 4 (2 – 6) |
| Smoking (%) | 12.7 | 11.3 |
| Blood pressure (mmHg) | ||
| Systolic | 128 (120 – 137) | 125 (113 – 136) |
| Diastolic | 79 (74 – 86) | 75 (68 – 82) |
| Body Mass Index (kg/m2) | 27.5 (25.2 – 30.3) | 25.6 (22.8 – 30.2) |
| Waist Circumference (cm) | 95.3 (88.9 – 104.1) | 81.3 (73.7 – 91.8) |
| Glucose (mg/dL) | 95.1 (88 – 103) | 91 (86 – 98) |
| Insulin (pmol/L) | 44.7 (29.5 – 67.0) | 37.9 (26.1 – 57.1) |
| HOMA-IR | 1.5 (1.0 – 2.3) | 1.3 (0.8 – 1.9) |
| Metabolic Syndrome* (%) | 28.8 | 22.1 |
| C Reactive Protein (mg/dl) | 1.1 (0.5 – 2.1) | 1.4 (0.6 – 3.7) |
| Adiponectin (µg/ml ) | 13.1 (8.9 – 18.0) | 21.4 (15.0 – 28.5) |
| Leptin (ng/ml) | 5.5 (3.2 – 8.3) | 15.9 (9.6 – 26.9) |
| Resistin (ng/ml) | 5.2 (3.8 – 6.9) | 5.9 (4.4 – 7.9) |
| Interleukin-6 (pg/ml) | 1.24 (0.80 – 1.9) | 1.30 (0.84 – 2.12) |
| Soluble TNF Receptor 2 (ng/ml) | 1.6 (1.4 – 1.9) | 1.7 (1.4 – 2.0) |
| Coronary Artery Calcification (CAC) | ||
| CAC Mean score (±SD) | 123 ± 328 | 41 ± 133 |
| CAC Median (IQR) | 6 (1 – 70) | 1 (0 – 13) |
| CAC >70% (%) | 39.4 | 38.0 |
*
Metabolic syndrome as defined by the National Cholesterol Education Program; definition based on fasting glucose cut-point of 110 mg/dL. HOMA-IR = homeostasis model assessment of insulin resistance; TNF = tumor necrosis factor.